Australia's Cyclopharm eyes best day in over a week on strong results

Cyclopharm

23/08/2021 06:19

** Shares of Cyclopharm Ltd  CYC.AX  rise as much as 2.7% to
A$1.685, their best intraday pct gain since Aug. 12
    ** Radiopharmaceutical co says https://bit.ly/384USnL HY
revenue up 47% at A$8.5 mln ($6.08 mln), driven by strong demand
for its products and services
    ** HY net loss after tax narrows to A$3.9 mln from loss of
A$5.6 mln last year, declares HY dividend of 0.5 AU cents per
share
    ** Expects U.S. FDA approval for Technegas in 2H22
    ** Technegas is used before a CT scan to detect blood clots
blocking an artery in the lungs
    ** Says "demand for Technegas will continue to grow across 
existing markets"
    ** Stock has fallen 34.4% this year, as of last close


($1 = 1.3970 Australian dollars)

 (Reporting by Aneetta Thomas in Bengaluru)
 ((Aneetta.Thomas@thomsonreuters.com;))